Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...